Tag: Selective FAAH inhibitor (clinical-stage)

  • PF-04457845

    Selective FAAH inhibitor (clinical-stage)

    A clinical-stage FAAH inhibitor; the most thoroughly studied FAAH inhibitor in human trials, including a tragic phase 1 fatality at Bial.

    Abstract

    PF-04457845 (CAS 1020315-31-4; molecular formula C20H21F3N4O3; molecular weight 422.40) is a covalent piperidine-urea FAAH inhibitor developed at Pfizer. The compound is selective for FAAH over other serine hydrolases and produces elevated plasma and brain N-acylethanolamides (anandamide, OEA, PEA) at clinical doses. Phase 1 and 2 clinical trials in osteoarthritis pain, fibromyalgia, and (more recently) cannabis use disorder have demonstrated FAAH target engagement and modest clinical effects in some indications. The compound is most associated with the broader FAAH inhibitor scrutiny following the 2016 Bial Pharmaceuticals tragedy in Rennes, where a different FAAH inhibitor (BIA-10-2474) caused one death and severe neurological injury in a phase 1 trial; the cause was attributed to off-target effects unique to BIA-10-2474, exonerating PF-04457845 specifically. Plasma half-life is approximately 14 hours. Used as the canonical clinical-stage FAAH inhibitor for translational research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.